



Journal of Immune Based Therapies, Vaccines and Antimicrobials



ISSN: 2168-1546



Journal Editorial Board

ISSN: 2168-1546 (Print), 2168-1554 (Online)

<http://www.scirp.org/journal/jibtva>

Editor-in-Chief

Prof. Ronald B. Moss

Ansun BioPharma Inc., USA

Executive Editor-in-Chief

Dr. Dennis Taub

Clinical Immunology Section, USA

Editorial Board

Prof. Jonathan Angel

University of Ottawa, Canada

Dr. Luz Pámela Blanco

University of Michigan, USA

Prof. Mario Clerichi

University of Milan, Italy

Prof. Steven Douglas

University of Pennsylvania, USA

Dr. Marc Gurwith

PaxVax, Inc., USA

Dr. Wayne R. Hogrefe

Clinical Trials Program, USA

Dr. Zhiwei Hu

Yale University, USA

Dr. Pankaj Kumar

University of Saskatchewan, Canada

Dr. Robert Malone

Beardsworth Consulting Group, Inc., USA

Dr. Godfred Menezes

Hail University, Saudi Arabia

Prof. Thomas Moll

Adamis Pharmaceuticals Corporation, USA

Prof. William J. Murphy

University of California, USA

Dr. Savita Nair

Fox Chase Cancer Center Temple Health, USA

Prof. Jose Ignacio Santos

National Autonomous University of Mexico, Mexico

Prof. Richard Schwartz

Michigan State University, USA

Prof. Sherven Sharma

University of California at Los Angeles, USA

Dr. Xiaobin Tang

Stanford University School of Medicine, USA

Table of Contents

Volume 3 Number 4

October 2014

Lymphocytes CD8+ Expression Mean Increases the Immunity against Cancer

A. Prayitno, A. Sari, L. Wahyuningsih, M. S. Fitria, O. P. Astirin, A. Mudigdo, S. T. Putra.....37

Journal of Immune Based Therapies, Vaccines and Antimicrobials (JIBTVA)

Journal Information

SUBSCRIPTIONS

The *Journal of Immune Based Therapies, Vaccines and Antimicrobials* (Online at Scientific Research Publishing, www.SciRP.org) is published quarterly by Scientific Research Publishing, Inc., USA.

Subscription rates:

Print: \$59 per issue.

To subscribe, please contact Journals Subscriptions Department, E-mail: sub@scirp.org

SERVICES

Advertisements

Advertisement Sales Department, E-mail: service@scirp.org

Reprints (minimum quantity 100 copies)

Reprints Co-ordinator, Scientific Research Publishing, Inc., USA.

E-mail: sub@scirp.org

COPYRIGHT

COPYRIGHT AND REUSE RIGHTS FOR THE FRONT MATTER OF THE JOURNAL:

Copyright © 2014 by Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY).

<http://creativecommons.org/licenses/by/4.0/>

COPYRIGHT FOR INDIVIDUAL PAPERS OF THE JOURNAL:

Copyright © 2014 by author(s) and Scientific Research Publishing Inc.

REUSE RIGHTS FOR INDIVIDUAL PAPERS:

Note: At SCIRP authors can choose between CC BY and CC BY-NC. Please consult each paper for its reuse rights.

DISCLAIMER OF LIABILITY

Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinion of Scientific Research Publishing, Inc. We assume no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. We expressly disclaim any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought.

PRODUCTION INFORMATION

For manuscripts that have been accepted for publication, please contact:

E-mail: jibtva@scirp.org



Journal of Immune Based Therapies, Vaccines and Antimicrobials

ISSN: 2168-1546 (Print) ISSN: 2168-1554 (Online)

<http://www.scirp.org/journal/jibtva>

Journal of Immune Based Therapies, Vaccines and Antimicrobial (JIBTVA) encompasses all clinical-and research-based aspects of immune based therapies, vaccines and antimicrobials. JIBTVA is an open access, peer-reviewed, online journal dedicated to all aspects of therapeutic and prophylactic applications of immunology and microbiology.

Editor-in-Chief

Prof. Ronald B. Moss

Ansun BioPharma Inc., USA

Subject Coverage

The aims of the JIBTVA are to advance the understanding and application of specific immunological mechanisms, the role of antigens and antigenic epitopes in eliciting biological responses, immune correlates of protection and activity, strategic regulatory and clinical development considerations, adjuvant development and strategies for use, formulations, delivery and devices associated with various immune and antimicrobial therapies as well as other issues and findings relating to accelerating the discovery and advance development through licensure, distribution and use of efficacious vaccines, immune based therapies (IBTs) and antimicrobials. The areas of vaccines, IBTs, and antimicrobials encompass a variety of disciplines, including infectious diseases, transplantation, cancer, allergic disorders, and autoimmune diseases.

- Allergic Diseases
- Autoimmune Diseases
- Cancer
- Immunologic Diseases
- Infectious Diseases
- Transplantation
- Vaccines

We are also interested in: 1) Short reports—2 - 5 page papers where an author can either present an idea with theoretical background but has not yet completed the research needed for a complete paper or preliminary data; 2) Book reviews—Comments and critiques.

Notes for Intending Authors

Submitted papers should not have been previously published nor be currently under consideration for publication elsewhere. Paper submission will be handled electronically through the website. All papers are refereed through a peer review process. For more details about the submissions, please access the website.

Website and E-Mail

<http://www.scirp.org/journal/jibtva>

Email: jibtva@scirp.org

What is SCIRP?

Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

What is Open Access?

All original research papers published by SCIRP are made freely and permanently accessible online immediately upon publication. To be able to provide open access journals, SCIRP defrays operation costs from authors and subscription charges only for its printed version. Open access publishing allows an immediate, worldwide, barrier-free, open access to the full text of research papers, which is in the best interests of the scientific community.

- High visibility for maximum global exposure with open access publishing model
- Rigorous peer review of research papers
- Prompt faster publication with less cost
- Guaranteed targeted, multidisciplinary audience



Website: <http://www.scirp.org>

Subscription: sub@scirp.org

Advertisement: service@scirp.org